|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009324,
umls-concept:C0030705,
umls-concept:C0035647,
umls-concept:C0036576,
umls-concept:C0205082,
umls-concept:C0205314,
umls-concept:C0418981,
umls-concept:C0449435,
umls-concept:C0449820,
umls-concept:C0543467,
umls-concept:C0679622,
umls-concept:C1274040,
umls-concept:C1527148
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2004-5-14
|
|
pubmed:abstractText |
The failure rate of medical therapy in severe ulcerative colitis is high. A risk index, to aid the identification of patients of not responding at an early stage to intravenous corticosteroid therapy, would be useful to facilitate second-line treatment or surgery.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0269-2813
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1079-87
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15142197-Adult,
pubmed-meshheading:15142197-Colitis, Ulcerative,
pubmed-meshheading:15142197-Cyclosporine,
pubmed-meshheading:15142197-Female,
pubmed-meshheading:15142197-Humans,
pubmed-meshheading:15142197-Immunosuppressive Agents,
pubmed-meshheading:15142197-Male,
pubmed-meshheading:15142197-Middle Aged,
pubmed-meshheading:15142197-Patient Selection,
pubmed-meshheading:15142197-Prognosis,
pubmed-meshheading:15142197-Regression Analysis,
pubmed-meshheading:15142197-Risk Assessment,
pubmed-meshheading:15142197-Treatment Failure
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery.
|
|
pubmed:affiliation |
University Department of Gastroenterology, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK. gho@ed.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
